Serum lipid and glucose profiles in HIV-positive Nigerian children
Identifieur interne : 000E51 ( Pmc/Corpus ); précédent : 000E50; suivant : 000E52Serum lipid and glucose profiles in HIV-positive Nigerian children
Auteurs : Olukemi O. Ige ; Christopher S. Yilgwan ; Augustine O. Ebonyi ; Ruth Adah ; Idris Adedeji ; Esther S. Yiltok ; Stephen Oguche ; Fidelia Bode-ThomasSource :
- Journal of Virus Eradication [ 2055-6640 ] ; ????.
Abstract
To describe the fasting serum lipid and glucose profiles of HIV-positive Nigerian children and determine the prevalence and risk factors for dyslipidaemia and hyperglycaemia, which are risk factors for cardiovascular diseases.
This was a comparative cross-sectional study carried out at the Paediatric Infectious Disease Clinic (PIDC) of the Jos University Teaching Hospital (JUTH) for HIV-positive children and at two primary schools in Jos for HIV-negative children as controls. One hundred and forty-two HIV-positive children aged 6–18 years and an equal number of controls were studied by determining their fasting serum lipid and glucose levels. The prevalence of dyslipidaemia and hyperglycaemia was determined and their risk factors obtained using multivariate logistic regression.
Mean triglyceride levels were significantly higher in HIV-positive children compared with controls at 87.2 mg/dL (95% confidence interval [CI] 79.4–95.0) and 68.1 mg/dL (95% CI 62.5–72.7), respectively (
HIV-positive children on antiretroviral (ARV) drugs, especially LPV/r, should have their lipids regularly monitored as those with dyslipidaemia stand the risk of subsequently developing cardiovascular diseases.
Url:
PubMed: 28758024
PubMed Central: 5518245
Links to Exploration step
PMC:5518245Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Serum lipid and glucose profiles in HIV-positive Nigerian children</title><author><name sortKey="Ige, Olukemi O" sort="Ige, Olukemi O" uniqKey="Ige O" first="Olukemi O" last="Ige">Olukemi O. Ige</name><affiliation><nlm:aff id="jve7-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Yilgwan, Christopher S" sort="Yilgwan, Christopher S" uniqKey="Yilgwan C" first="Christopher S" last="Yilgwan">Christopher S. Yilgwan</name><affiliation><nlm:aff id="jve7-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Ebonyi, Augustine O" sort="Ebonyi, Augustine O" uniqKey="Ebonyi A" first="Augustine O" last="Ebonyi">Augustine O. Ebonyi</name><affiliation><nlm:aff id="jve7-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Adah, Ruth" sort="Adah, Ruth" uniqKey="Adah R" first="Ruth" last="Adah">Ruth Adah</name><affiliation><nlm:aff id="jve7-aff-0002"></nlm:aff></affiliation></author><author><name sortKey="Adedeji, Idris" sort="Adedeji, Idris" uniqKey="Adedeji I" first="Idris" last="Adedeji">Idris Adedeji</name><affiliation><nlm:aff id="jve7-aff-0003"></nlm:aff></affiliation></author><author><name sortKey="Yiltok, Esther S" sort="Yiltok, Esther S" uniqKey="Yiltok E" first="Esther S" last="Yiltok">Esther S. Yiltok</name><affiliation><nlm:aff id="jve7-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Oguche, Stephen" sort="Oguche, Stephen" uniqKey="Oguche S" first="Stephen" last="Oguche">Stephen Oguche</name><affiliation><nlm:aff id="jve7-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Bode Thomas, Fidelia" sort="Bode Thomas, Fidelia" uniqKey="Bode Thomas F" first="Fidelia" last="Bode-Thomas">Fidelia Bode-Thomas</name><affiliation><nlm:aff id="jve7-aff-0001"></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">28758024</idno><idno type="pmc">5518245</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518245</idno><idno type="RBID">PMC:5518245</idno><date when="????">????</date><idno type="wicri:Area/Pmc/Corpus">000E51</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000E51</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Serum lipid and glucose profiles in HIV-positive Nigerian children</title><author><name sortKey="Ige, Olukemi O" sort="Ige, Olukemi O" uniqKey="Ige O" first="Olukemi O" last="Ige">Olukemi O. Ige</name><affiliation><nlm:aff id="jve7-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Yilgwan, Christopher S" sort="Yilgwan, Christopher S" uniqKey="Yilgwan C" first="Christopher S" last="Yilgwan">Christopher S. Yilgwan</name><affiliation><nlm:aff id="jve7-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Ebonyi, Augustine O" sort="Ebonyi, Augustine O" uniqKey="Ebonyi A" first="Augustine O" last="Ebonyi">Augustine O. Ebonyi</name><affiliation><nlm:aff id="jve7-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Adah, Ruth" sort="Adah, Ruth" uniqKey="Adah R" first="Ruth" last="Adah">Ruth Adah</name><affiliation><nlm:aff id="jve7-aff-0002"></nlm:aff></affiliation></author><author><name sortKey="Adedeji, Idris" sort="Adedeji, Idris" uniqKey="Adedeji I" first="Idris" last="Adedeji">Idris Adedeji</name><affiliation><nlm:aff id="jve7-aff-0003"></nlm:aff></affiliation></author><author><name sortKey="Yiltok, Esther S" sort="Yiltok, Esther S" uniqKey="Yiltok E" first="Esther S" last="Yiltok">Esther S. Yiltok</name><affiliation><nlm:aff id="jve7-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Oguche, Stephen" sort="Oguche, Stephen" uniqKey="Oguche S" first="Stephen" last="Oguche">Stephen Oguche</name><affiliation><nlm:aff id="jve7-aff-0001"></nlm:aff></affiliation></author><author><name sortKey="Bode Thomas, Fidelia" sort="Bode Thomas, Fidelia" uniqKey="Bode Thomas F" first="Fidelia" last="Bode-Thomas">Fidelia Bode-Thomas</name><affiliation><nlm:aff id="jve7-aff-0001"></nlm:aff></affiliation></author></analytic><series><title level="j">Journal of Virus Eradication</title><idno type="ISSN">2055-6640</idno><idno type="eISSN">2055-6659</idno><imprint><date when="????">????</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>Abstract</title><sec id="jve7-sec-0001"><title id="jve7-title-0002">Objectives</title><p id="jve7-para-0001">To describe the fasting serum lipid and glucose profiles of HIV-positive Nigerian children and determine the prevalence and risk factors for dyslipidaemia and hyperglycaemia, which are risk factors for cardiovascular diseases.</p></sec><sec id="jve7-sec-0002"><title id="jve7-title-0003">Methods</title><p id="jve7-para-0002">This was a comparative cross-sectional study carried out at the Paediatric Infectious Disease Clinic (PIDC) of the Jos University Teaching Hospital (JUTH) for HIV-positive children and at two primary schools in Jos for HIV-negative children as controls. One hundred and forty-two HIV-positive children aged 6–18 years and an equal number of controls were studied by determining their fasting serum lipid and glucose levels. The prevalence of dyslipidaemia and hyperglycaemia was determined and their risk factors obtained using multivariate logistic regression. <italic>P</italic> values of less than 0.05 were considered statistically significant.</p></sec><sec id="jve7-sec-0003"><title id="jve7-title-0004">Results</title><p id="jve7-para-0003">Mean triglyceride levels were significantly higher in HIV-positive children compared with controls at 87.2 mg/dL (95% confidence interval [CI] 79.4–95.0) and 68.1 mg/dL (95% CI 62.5–72.7), respectively (<italic>P</italic><0.001). There were no significant differences in mean glucose levels. Dyslipidaemia was significantly higher in HIV-positive children (21.8%) compared with controls (12.7%; <italic>P=</italic>0.04). Total serum cholesterol was elevated in 17 (12.0%) HIV-positive participants compared with seven (4.9%) of controls (<italic>P=</italic>0.02). Children on lopinavir/ritonavir (LPV/r) and those with no significant or mild disease had a significantly higher prevalence of hypercholesterolaemia (33.3% <italic>vs</italic> 4.8% and 14.5% <italic>vs</italic> 0.0%, respectively; <italic>P</italic><0.001).</p></sec><sec id="jve7-sec-0004"><title id="jve7-title-0005">Conclusion</title><p id="jve7-para-0004">HIV-positive children on antiretroviral (ARV) drugs, especially LPV/r, should have their lipids regularly monitored as those with dyslipidaemia stand the risk of subsequently developing cardiovascular diseases.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Martin, Ar" uniqKey="Martin A">AR Martin</name></author><author><name sortKey="Siliciano, Rf" uniqKey="Siliciano R">RF. Siliciano</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Grinspoon, S" uniqKey="Grinspoon S">S Grinspoon</name></author><author><name sortKey="Carr, A" uniqKey="Carr A">A. Carr</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="May, Mt" uniqKey="May M">MT May</name></author><author><name sortKey="Gompels, M" uniqKey="Gompels M">M Gompels</name></author><author><name sortKey="Delpech, V" uniqKey="Delpech V">V Delpech</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Francisci, D" uniqKey="Francisci D">D Francisci</name></author><author><name sortKey="Giannini, S" uniqKey="Giannini S">S Giannini</name></author><author><name sortKey="Baldelli, F" uniqKey="Baldelli F">F Baldelli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Husain, Ne" uniqKey="Husain N">NE Husain</name></author><author><name sortKey="Ahmed, Mh" uniqKey="Ahmed M">MH. Ahmed</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bernstein, L" uniqKey="Bernstein L">L Bernstein</name></author><author><name sortKey="Brook, K" uniqKey="Brook K">K Brook</name></author><author><name sortKey="Collado" uniqKey="Collado">Collado</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cunha, J" uniqKey="Cunha J">J Cunha</name></author><author><name sortKey="Maselli, Lm" uniqKey="Maselli L">LM Maselli</name></author><author><name sortKey="Stern, Ac" uniqKey="Stern A">AC Stern</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Alomar, Mj" uniqKey="Alomar M">MJ. Alomar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nery, Mw" uniqKey="Nery M">MW Nery</name></author><author><name sortKey="Martelli, Cm" uniqKey="Martelli C">CM Martelli</name></author><author><name sortKey="Silveira, Ea" uniqKey="Silveira E">EA Silveira</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Shea, S" uniqKey="Shea S">S Shea</name></author><author><name sortKey="Ottman, R" uniqKey="Ottman R">R Ottman</name></author><author><name sortKey="Gabrieli, C" uniqKey="Gabrieli C">C Gabrieli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Olusanya, O" uniqKey="Olusanya O">O Olusanya</name></author><author><name sortKey="Okpere, E" uniqKey="Okpere E">E Okpere</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Eknoyan, G" uniqKey="Eknoyan G">G. Eknoyan</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Chu, C" uniqKey="Chu C">C Chu</name></author><author><name sortKey="Umanski, G" uniqKey="Umanski G">G Umanski</name></author><author><name sortKey="Blank, A" uniqKey="Blank A">A Blank</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mandal, A" uniqKey="Mandal A">A Mandal</name></author><author><name sortKey="Mukherjee, A" uniqKey="Mukherjee A">A Mukherjee</name></author><author><name sortKey="Lakshmy, R" uniqKey="Lakshmy R">R Lakshmy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Menezes De Padua, Ca" uniqKey="Menezes De Padua C">CA Menezes de Padua</name></author><author><name sortKey="Moura, Cs" uniqKey="Moura C">CS. Moura</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Blazquez, D" uniqKey="Blazquez D">D Blazquez</name></author><author><name sortKey="Ramos Amador, Jt" uniqKey="Ramos Amador J">JT Ramos-Amador</name></author><author><name sortKey="Sainz, T" uniqKey="Sainz T">T Sainz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Piloya, T" uniqKey="Piloya T">T Piloya</name></author><author><name sortKey="Bakeera Kitaka, S" uniqKey="Bakeera Kitaka S">S Bakeera-Kitaka</name></author><author><name sortKey="Kekitiinwa, A" uniqKey="Kekitiinwa A">A Kekitiinwa</name></author><author><name sortKey="Kamya, Mr" uniqKey="Kamya M">MR. Kamya</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tremeschin, Mh" uniqKey="Tremeschin M">MH Tremeschin</name></author><author><name sortKey="Sartorelli, Ds" uniqKey="Sartorelli D">DS Sartorelli</name></author><author><name sortKey="Cervi, Mc" uniqKey="Cervi M">MC Cervi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Aldrovandi, Gm" uniqKey="Aldrovandi G">GM Aldrovandi</name></author><author><name sortKey="Lindsey, Jc" uniqKey="Lindsey J">JC Lindsey</name></author><author><name sortKey="Jacobson, Dl" uniqKey="Jacobson D">DL Jacobson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carter, Rj" uniqKey="Carter R">RJ Carter</name></author><author><name sortKey="Wiener, J" uniqKey="Wiener J">J Wiener</name></author><author><name sortKey="Abrams, Ej" uniqKey="Abrams E">EJ Abrams</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kamara, Da" uniqKey="Kamara D">DA Kamara</name></author><author><name sortKey="Smith, C" uniqKey="Smith C">C Smith</name></author><author><name sortKey="Ryom, L" uniqKey="Ryom L">L Ryom</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bwakura Dangarembizi, M" uniqKey="Bwakura Dangarembizi M">M Bwakura-Dangarembizi</name></author><author><name sortKey="Musiime, V" uniqKey="Musiime V">V Musiime</name></author><author><name sortKey="Szubert, Aj" uniqKey="Szubert A">AJ Szubert</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rose, H" uniqKey="Rose H">H Rose</name></author><author><name sortKey="Woolley, I" uniqKey="Woolley I">I Woolley</name></author><author><name sortKey="Hoy, J" uniqKey="Hoy J">J Hoy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brewinski, M" uniqKey="Brewinski M">M Brewinski</name></author><author><name sortKey="Megazzini, K" uniqKey="Megazzini K">K Megazzini</name></author><author><name sortKey="Hance, Lf" uniqKey="Hance L">LF Hance</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hazra, R" uniqKey="Hazra R">R Hazra</name></author><author><name sortKey="Cohen, Ra" uniqKey="Cohen R">RA Cohen</name></author><author><name sortKey="Gonin, R" uniqKey="Gonin R">R Gonin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Viganoa, Tc" uniqKey="Viganoa T">TC Viganoa</name></author><author><name sortKey="Brambilla, P" uniqKey="Brambilla P">P Brambilla</name></author><author><name sortKey="Newell, Ml" uniqKey="Newell M">ML. Newell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lee, B" uniqKey="Lee B">B Lee</name></author><author><name sortKey="Aurpibul, L" uniqKey="Aurpibul L">L Aurpibul</name></author><author><name sortKey="Sirisanthana, V" uniqKey="Sirisanthana V">V Sirisanthana</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Papi, L" uniqKey="Papi L">L Papi</name></author><author><name sortKey="Menezes, Ac" uniqKey="Menezes A">AC Menezes</name></author><author><name sortKey="Rocha, H" uniqKey="Rocha H">H Rocha</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Galindo, J" uniqKey="Galindo J">J Galindo</name></author><author><name sortKey="Amariles, P" uniqKey="Amariles P">P Amariles</name></author><author><name sortKey="Mueses Marin, Hf" uniqKey="Mueses Marin H">HF Mueses-Marin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Grunfeld, C" uniqKey="Grunfeld C">C Grunfeld</name></author><author><name sortKey="Pang, M" uniqKey="Pang M">M Pang</name></author><author><name sortKey="Doerrler, W" uniqKey="Doerrler W">W Doerrler</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kimani Murage, Ew" uniqKey="Kimani Murage E">EW Kimani-Murage</name></author><author><name sortKey="Norris, Sa" uniqKey="Norris S">SA Norris</name></author><author><name sortKey="Pettifor, Jm" uniqKey="Pettifor J">JM Pettifor</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Legg, C" uniqKey="Legg C">C Legg</name></author><author><name sortKey="Kormawa, P" uniqKey="Kormawa P">P Kormawa</name></author><author><name sortKey="Maziya Dixon, B" uniqKey="Maziya Dixon B">B Maziya-Dixon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Feinstein, Js" uniqKey="Feinstein J">JS. Feinstein</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mitter, Ss" uniqKey="Mitter S">SS Mitter</name></author><author><name sortKey="Vedanthan, R" uniqKey="Vedanthan R">R Vedanthan</name></author><author><name sortKey="Islami, F" uniqKey="Islami F">F Islami</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Martinez, E" uniqKey="Martinez E">E Martinez</name></author><author><name sortKey="Garcia Viejo, Ma" uniqKey="Garcia Viejo M">MA Garcia-Viejo</name></author><author><name sortKey="Blanco, Jl" uniqKey="Blanco J">JL Blanco</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Xiang, N" uniqKey="Xiang N">N Xiang</name></author><author><name sortKey="James, M" uniqKey="James M">M James</name></author><author><name sortKey="Walters, S" uniqKey="Walters S">S Walters</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="editorial"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">J Virus Erad</journal-id><journal-id journal-id-type="iso-abbrev">J Virus Erad</journal-id><journal-id journal-id-type="publisher-id">JOURNAL OF VIRUS ERADICATION</journal-id><journal-title-group><journal-title>Journal of Virus Eradication</journal-title></journal-title-group><issn pub-type="ppub">2055-6640</issn><issn pub-type="epub">2055-6659</issn><publisher><publisher-name>Mediscript Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28758024</article-id><article-id pub-id-type="pmc">5518245</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Serum lipid and glucose profiles in HIV-positive Nigerian children</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ige</surname><given-names>Olukemi O</given-names></name><xref ref-type="aff" rid="jve7-aff-0001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yilgwan</surname><given-names>Christopher S</given-names></name><xref ref-type="aff" rid="jve7-aff-0001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ebonyi</surname><given-names>Augustine O</given-names></name><xref ref-type="aff" rid="jve7-aff-0001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Adah</surname><given-names>Ruth</given-names></name><xref ref-type="aff" rid="jve7-aff-0002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Adedeji</surname><given-names>Idris</given-names></name><xref ref-type="aff" rid="jve7-aff-0003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yiltok</surname><given-names>Esther S</given-names></name><xref ref-type="aff" rid="jve7-aff-0001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Oguche</surname><given-names>Stephen</given-names></name><xref ref-type="aff" rid="jve7-aff-0001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bode-Thomas</surname><given-names>Fidelia</given-names></name><xref ref-type="aff" rid="jve7-aff-0001"><sup>1</sup></xref><xref ref-type="corresp" rid="an1">*</xref></contrib><aff id="jve7-aff-0001"><label><sup>1</sup></label><institution>Department of Paediatrics</institution>,<institution>University of Jos</institution>,<country>Nigeria</country></aff><aff id="jve7-aff-0002"><label><sup>2</sup></label><institution>Department of Paediatrics</institution>,<institution>Jos University Teaching Hospital</institution>,<country>Nigeria</country></aff><aff id="jve7-aff-0003"><label><sup>3</sup></label><institution>Abubakar Tafawa Balewa Teaching Hospital</institution>,<addr-line>Bauchi</addr-line>,<country>Nigeria</country></aff></contrib-group><author-notes><corresp id="an1"><label>*</label>Corresponding author: Fidelia Bode-Thomas,
<institution>Department of Paediatrics</institution>,
<institution>University of Jos</institution>,
<addr-line>Jos</addr-line>,
<addr-line>Plateau State</addr-line>,
<country>Nigeria</country>Email:
<email>bodefide@yahoo.com</email></corresp></author-notes><pub-date date-type="collection" publication-format="electronic"><month>7</month><year>2017</year></pub-date><pub-date date-type="pub" publication-format="electronic"><day>1</day><month>7</month><year>2017</year></pub-date><volume>3</volume><issue>3</issue><fpage>157</fpage><lpage>162</lpage><permissions><copyright-statement>© 2017 The Authors. <italic>Journal of Virus Eradication</italic> published by Mediscript Ltd</copyright-statement><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an open access article published under the terms of a Creative Commons License.</license-p></license></permissions><abstract id="jve7-abs-0001"><title>Abstract</title><sec id="jve7-sec-0001"><title id="jve7-title-0002">Objectives</title><p id="jve7-para-0001">To describe the fasting serum lipid and glucose profiles of HIV-positive Nigerian children and determine the prevalence and risk factors for dyslipidaemia and hyperglycaemia, which are risk factors for cardiovascular diseases.</p></sec><sec id="jve7-sec-0002"><title id="jve7-title-0003">Methods</title><p id="jve7-para-0002">This was a comparative cross-sectional study carried out at the Paediatric Infectious Disease Clinic (PIDC) of the Jos University Teaching Hospital (JUTH) for HIV-positive children and at two primary schools in Jos for HIV-negative children as controls. One hundred and forty-two HIV-positive children aged 6–18 years and an equal number of controls were studied by determining their fasting serum lipid and glucose levels. The prevalence of dyslipidaemia and hyperglycaemia was determined and their risk factors obtained using multivariate logistic regression. <italic>P</italic> values of less than 0.05 were considered statistically significant.</p></sec><sec id="jve7-sec-0003"><title id="jve7-title-0004">Results</title><p id="jve7-para-0003">Mean triglyceride levels were significantly higher in HIV-positive children compared with controls at 87.2 mg/dL (95% confidence interval [CI] 79.4–95.0) and 68.1 mg/dL (95% CI 62.5–72.7), respectively (<italic>P</italic><0.001). There were no significant differences in mean glucose levels. Dyslipidaemia was significantly higher in HIV-positive children (21.8%) compared with controls (12.7%; <italic>P=</italic>0.04). Total serum cholesterol was elevated in 17 (12.0%) HIV-positive participants compared with seven (4.9%) of controls (<italic>P=</italic>0.02). Children on lopinavir/ritonavir (LPV/r) and those with no significant or mild disease had a significantly higher prevalence of hypercholesterolaemia (33.3% <italic>vs</italic> 4.8% and 14.5% <italic>vs</italic> 0.0%, respectively; <italic>P</italic><0.001).</p></sec><sec id="jve7-sec-0004"><title id="jve7-title-0005">Conclusion</title><p id="jve7-para-0004">HIV-positive children on antiretroviral (ARV) drugs, especially LPV/r, should have their lipids regularly monitored as those with dyslipidaemia stand the risk of subsequently developing cardiovascular diseases.</p></sec></abstract><kwd-group kwd-group-type="author"><title id="jve7-title-0006">Keywords</title><kwd>dyslipidaemia</kwd><kwd>hyperglycaemia</kwd><kwd>cardiovascular disease risk</kwd><kwd>HIV-positive children</kwd><kwd>Nigeria</kwd></kwd-group></article-meta></front><body><sec id="jve7-sec-0005"><title id="jve7-title-0007">Introduction</title><p id="jve7-para-0005">With approximately 35 million individuals being infected with HIV/AIDS worldwide, the dangers of this disease cannot be overemphasised <xref rid="jve7-bib-0001" ref-type="bibr">[1]</xref>. Two-thirds of these individuals live in sub-Saharan Africa and in 2014, an estimated 3.4 million individuals were living with HIV/AIDS in Nigeria, approximately 10% of whom were children <xref rid="jve7-bib-0002" ref-type="bibr">[2]</xref>.</p><p id="jve7-para-0006">The improvement in the survival rates for both adults and children living with HIV resulting from the use of antiretroviral (ARV) drugs has brought with it the metabolic effects of some of these drugs including hyperglycaemia and dyslipidaemia including increased total cholesterol (hypercholesterolaemia), increased low density lipoprotein cholesterol (LDL-c), decreased high density lipoprotein cholesterol (HDL-c) and hypertriglyceridaemia. These effects are established risk factors for cardiovascular diseases (CVDs) such as coronary artery disease, myocardial infarction, angina and stroke as they promote plaque formation, leading to arterial narrowing, which can contribute to significant morbidity and mortality later in life <xref rid="jve7-bib-0003" ref-type="bibr">[3,4]</xref>. In addition to the effects of ARVs, HIV itself can also directly induce endothelial cell injury resulting in arterial plaque formation <xref rid="jve7-bib-0005" ref-type="bibr">[5]</xref>. HIV-positive children may have a higher risk of developing CVD later in life than HIV-negative children as a result of these metabolic complications.</p><p id="jve7-para-0007">Dyslipidaemia and hyperglycaemia have been shown to be more prevalent in individuals with HIV/AIDS, especially those on ARVs, compared with the general population <xref rid="jve7-bib-0006" ref-type="bibr">[6]</xref>. All classes of ARV have been shown to be associated with metabolic effects but protease inhibitors (PIs) are particularly associated with the development of hyperlipidaemia because they inhibit differentiation of adipocytes and increase lipolysis leading to hypercholesterolaemia, hypertriglyceridaemia and an increase in LDL cholesterol <xref rid="jve7-bib-0007" ref-type="bibr">[7]</xref>. PIs also reduce glucose transportation inducing insulin resistance (IR), which will lead to hyperglycaemia <xref rid="jve7-bib-0007" ref-type="bibr">[7,8]</xref>. The nucleoside inhibitors of retrotranscriptase (NRTIs), especially stavudine (d4T), also inhibit mitochondrial DNA polymerase within adipocytes that results in mitochondrial injury, and this leads to hypercholesterolaemia and hypertriglyceridaemia <xref rid="jve7-bib-0008" ref-type="bibr">[8]</xref>.</p><p id="jve7-para-0008">The metabolic effects of HIV and/or ARV drugs in HIV-positive children in Jos, Nigeria has, however, not been studied and currently data on the lipid and glucose profile in the Nigerian paediatric HIV population are sparse <xref rid="jve7-bib-0009" ref-type="bibr">[9]</xref>. Closing the knowledge gap will help in adequate screening and risk stratification of these children in order to prevent later development of CVD <xref rid="jve7-bib-0010" ref-type="bibr">[10]</xref>. The present study, therefore, aims to describe the prevalence and risk factors for dyslipidaemia and hyperglycaemia in HIV-positive Nigerian children compared with age- and sex-matched controls. This would help to improve the level of care in these children and open opportunities for further longitudinal research.</p></sec><sec id="jve7-sec-0006"><title id="jve7-title-0008">Methods</title><sec id="jve7-sec-0007"><title id="jve7-title-0009">Study population and site</title><p id="jve7-para-0009">Children aged 6–18 years of age and on follow-up at the Paediatric Infectious Disease Clinic (PIDC) of the AIDS Prevention Initiative in Nigeria/President's Emergency Program For AIDS Relief (APIN/PEPFAR) of the Jos University Teaching Hospital in Nigeria were recruited into the study. The PIDC serves children, infected or exposed to HIV/AIDS who live in Jos, the capital of Plateau State, its environs and also neighbouring states in the north-central part of Nigeria.</p><p id="jve7-para-0010">One hundred and forty-two HIV-positive children were selected sequentially as they presented to the clinic. An equal number of, presumably healthy, HIV-negative age- and sex-matched controls from primary/secondary schools were recruited for the study.</p><p id="jve7-para-0011">Inclusion criteria:
<list list-type="simple" id="jve7-list-0001"><list-item id="jve7-li-0001"><label>■</label><p id="jve7-para-0012">HIV-positive children, 6–18 years as participants</p></list-item><list-item id="jve7-li-0002"><label>■</label><p id="jve7-para-0013">HIV-negative children, 6–18 years as controls</p></list-item><list-item id="jve7-li-0003"><label>■</label><p id="jve7-para-0014">Children whose primary caregiver had given consent/assent</p></list-item></list>Exclusion criteria:
<list list-type="simple" id="jve7-list-0002"><list-item id="jve7-li-0004"><label>■</label><p id="jve7-para-0015">Children <6 years of age</p></list-item><list-item id="jve7-li-0005"><label>■</label><p id="jve7-para-0016">Members of the control group who tested positive for HIV infection</p></list-item><list-item id="jve7-li-0006"><label>■</label><p id="jve7-para-0017">Members of the control group with any known chronic medical illness</p></list-item></list></p></sec><sec id="jve7-sec-0008"><title id="jve7-title-0010">Biodata and anthropometry</title><p id="jve7-para-0018">A history of first- or second-hand smoking was obtained. First-hand smoking is defined as smoke inhaled directly by the smoker while second-hand smoking is defined as a combination of smoke from the burning end of a cigarette and the smoke breathed out by smokers who live with children <xref rid="jve7-bib-0011" ref-type="bibr">[11]</xref>. A known family history of CVD including hypertension, sudden heart attack and stroke was also obtained from the primary caregiver or by phone call to a first-degree relative <xref rid="jve7-bib-0012" ref-type="bibr">[12]</xref>. The socio-economic status of the children was obtained using the Olusanya classification <xref rid="jve7-bib-0013" ref-type="bibr">[13]</xref>.</p><p id="jve7-para-0019">Weight and height were measured using standard methods and the Quetelet index was used to calculate body mass index (BMI) <xref rid="jve7-bib-0014" ref-type="bibr">[14]</xref>. Further data obtained on the HIV-positive participants included CD4 cell count, viral load, World Health Organization (WHO)-defined clinical and immunological stages of the disease and ARV drugs used by the children <xref rid="jve7-bib-0015" ref-type="bibr">[15]</xref>. All data obtained were recorded on a predesigned questionnaire.</p></sec><sec id="jve7-sec-0009"><title id="jve7-title-0011">Laboratory investigations</title><p id="jve7-para-0020">A serum lipid profile that included total cholesterol, HDL-cholesterol (HDL-c), LDL-cholesterol (LDL-c) and triglycerides (TG), and glucose was analysed from a fasting blood sample using the enzymatic colorimetric assay and hexokinase G6PDH/UV method, respectively. The equipment used for the analysis was the Roche Cobas 311 manufactured in 2002.</p><p id="jve7-para-0021">Hypercholesterolaemia was defined as a total cholesterol level ≥200 mg/dL and a serum triglyceride level ≥150 mg/dL was considered as hypertriglyceridaemia. Increased LDL-c and decreased HDL-c were defined as levels ≥130 mg/dL and <40 mg/dL, respectively <xref rid="jve7-bib-0016" ref-type="bibr">[16]</xref>. Dyslipidaemia was said to be present if the child had any of the lipid abnormalities. Hyperglycaemia was defined as a fasting blood sugar (FBS) >110mg/dL <xref rid="jve7-bib-0016" ref-type="bibr">[16]</xref>.</p><p id="jve7-para-0022">For HIV-positive children, a CD4 cell count performed within a 3 month period from the time of study and the worst ever clinical stage of disease were obtained from the case records of each participant and documented. Using WHO criteria, CD4 cell counts for each child were used to characterise current immunological stage into ‘not significant’ (>500 cells/mm<sup>3</sup>), ‘mild’ (350–499 cells/mm<sup>3</sup>), ‘advanced’ (201–349 cells/mm<sup>3</sup>) or ‘severe’ <200 cells/mm<sup>3</sup> immunodeficiency <xref rid="jve7-bib-0015" ref-type="bibr">[15]</xref>. Blood samples were taken from the control group to assess their HIV status using the rapid diagnostic test after pre-test counselling. Two children were found to be positive and sent to a tertiary hospital for further testing and evaluation.</p></sec></sec><sec id="jve7-sec-0010"><title id="jve7-title-0012">Ethical considerations</title><p id="jve7-para-0023">Ethical clearance was obtained from the Jos University Teaching Hospital Ethical Review Board. Written and informed consent was obtained from the parents and, subsequently, assent from all the children. Consent was obtained from the parents of members of the control group to perform HIV testing on their children.</p><sec id="jve7-sec-0011"><title id="jve7-title-0013">Statistical analysis</title><p id="jve7-para-0024">Data were entered into the Epi Info 7.0 statistical software. Frequency tables were used to present qualitative data while quantitative data was presented using the mean and 95% confidence interval (CI). A chi-squared statistical test was used to determine the relationship between dyslipidaemia and certain risk factors. Bivariate logistic regression was used to initially identify variables associated with each outcome: variables that were significantly associated with the outcome were then fitted into a multivariate logistic regression model to determine the risk factors for dyslipidaemia. Odds ratio (OR) with their CI were obtained and<italic> P</italic> values ≤0.05 were considered statistically significant.</p></sec></sec><sec id="jve7-sec-0012"><title id="jve7-title-0014">Results</title><sec id="jve7-sec-0013"><title id="jve7-title-0015">Characteristics of study population</title><p id="jve7-para-0025">The two groups comprising 142 HIV-positive children (69 males, 48.6%; 73 females, 51.4%) and the same number of HIV-negative children both had a male to female ratio of 1.1:1 and a mean age at enrolment of 10.6 years (95% CI 10.1–11.1) and 10.8 years (95% CI 10.3–11.3), respectively (<italic>P</italic>=0.64). HIV-positive children were from a significantly lower socio-economic group compared with the controls (<italic>P</italic><0.001). The prevalence of second-hand smoking was significantly higher in HIV-positive children (16.9% <italic>vs</italic> 2.8%, respectively, <italic>P</italic><0.001) but there was no difference in the presence of a known family history of CVD in the two groups (<italic>P</italic>=0.53) (Table <xref ref-type="table" rid="jve7-tbl-0001">1</xref>).</p><table-wrap id="jve7-tbl-0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p id="jve7-para-0026">Socio-demographic characteristics of 142 HIV-positive children and age and sex-matched HIV-negative controls</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col></colgroup><thead><tr><th rowspan="3" colspan="1">Characteristics</th><th rowspan="1" colspan="1">Total participants</th><th rowspan="1" colspan="1">HIV-positive participants</th><th rowspan="1" colspan="1">HIV-negative participants</th><th rowspan="3" colspan="1"><italic>P</italic></th></tr><tr><th rowspan="1" colspan="1">=284</th><th rowspan="1" colspan="1">=142</th><th rowspan="1" colspan="1">=142</th></tr><tr><th rowspan="1" colspan="1"><italic>n</italic> (%)</th><th rowspan="1" colspan="1"><italic>n</italic> (%)</th><th rowspan="1" colspan="1"><italic>n</italic> (%)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Mean age in years (95%CI)</td><td rowspan="1" colspan="1">10.7(10.3–11.1)</td><td rowspan="1" colspan="1">10.6(10.1–11.1)</td><td rowspan="1" colspan="1">10.8(10.3–11.3)</td><td rowspan="1" colspan="1">0.64</td></tr><tr><td rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Male</td><td rowspan="1" colspan="1">138(48.6)</td><td rowspan="1" colspan="1">69(48.6)</td><td rowspan="1" colspan="1">69(48.6)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Female</td><td rowspan="1" colspan="1">146(51.4)</td><td rowspan="1" colspan="1">73(51.4)</td><td rowspan="1" colspan="1">73(51.4)</td><td rowspan="1" colspan="1">1.0</td></tr><tr><td rowspan="1" colspan="1">Socio-economic status</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Upper</td><td rowspan="1" colspan="1">109(39.2)</td><td rowspan="1" colspan="1">24(16.9)</td><td rowspan="1" colspan="1">85(61.2)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Middle</td><td rowspan="1" colspan="1">79(28.4)</td><td rowspan="1" colspan="1">36(25.4)</td><td rowspan="1" colspan="1">43(30.9)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Lower</td><td rowspan="1" colspan="1">90(32.4)</td><td rowspan="1" colspan="1">82(57.8)</td><td rowspan="1" colspan="1">11(7.9)</td><td rowspan="1" colspan="1"><0.001</td></tr><tr><td rowspan="1" colspan="1">Second-hand smoking</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Yes</td><td rowspan="1" colspan="1">28(9.9)</td><td rowspan="1" colspan="1">24(16.9)</td><td rowspan="1" colspan="1">4(2.8)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> No</td><td rowspan="1" colspan="1">256(90.1)</td><td rowspan="1" colspan="1">118(83.1)</td><td rowspan="1" colspan="1">138(97.2)</td><td rowspan="1" colspan="1"><0.001</td></tr><tr><td rowspan="1" colspan="1">Known family history of heart disease</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Yes</td><td rowspan="1" colspan="1">97(34.2)</td><td rowspan="1" colspan="1">51(35.9)</td><td rowspan="1" colspan="1">46(32.4)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> No</td><td rowspan="1" colspan="1">183(64.4)</td><td rowspan="1" colspan="1">87(61.3)</td><td rowspan="1" colspan="1">96(67.6)</td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Unknown</td><td rowspan="1" colspan="1">4(1.4)</td><td rowspan="1" colspan="1">4(2.8)</td><td rowspan="1" colspan="1">4(2.8)</td><td rowspan="1" colspan="1">0.53</td></tr><tr><td rowspan="1" colspan="1">ARV therapy</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">140(98.6)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1">First-line drugs</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">104(72.3)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> NVP+3TC+ZDV</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">64(45.1)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> ZDV+3TC+EFV</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">34(23.9)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> 3TC+EFV+ABC</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">4(2.8)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> NVP+3TC+d4T</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">1(0.7)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> NVP+3TC+ABC</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">1(0.7)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1">Second-line drugs</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> 3TC+ABC+LPV/r</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">36(25.4)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr></tbody></table><table-wrap-foot><fn id="jve7-fn-0001"><p id="jve7-para-0027">ARV: antiretroviral; ABC: abacavir; d4T: stavudine; EFV: efavirenz; LPV/r: lopinavir/ritonavir; NVP: nevirapine; ZDV: zidovudine; 3TC: lamivudine</p></fn></table-wrap-foot></table-wrap><p id="jve7-para-0028">A total of 140 (98.6%) HIV-positive children were on ARV drugs while two (1.4%) were not. Of the 140 on ARV drugs, 104 (72.6%) were on first-line drug therapy with a combination of two NRTIs and one non-nucleoside reverse transcriptase inhibitor (NNRTI) while 36 (25.7%) participants were on second-line drugs – two NRTIs and one PI, lopinavir/ ritonavir (LPV/r). The various combinations of ARV drugs received by the participants are shown in Table <xref ref-type="table" rid="jve7-tbl-0001">1</xref>.</p><p id="jve7-para-0029">The HIV-positive participants had a mean age at diagnosis of 4.9 years (95% CI 4.2–5.6) and a mean current CD4 cell count of 698.4 cells/mm<sup>3</sup> (95% CI 633.6–763.2). Sixty-four (45.1%) participants had a WHO clinical stage of 1, while 26 (18.3%), 46 (32.4%) and 6 (4.2%) had clinical stage 2, 3 and 4, respectively. For the current WHO immunological stage of disease, 97 (68.3%) children had no significant immunodeficiency, while 20 (14.1%) had mild disease and 11 (7.7%) and 14 (9.9%) had advanced and severe disease, respectively. All HIV-positive children were likely to have been infected perinatally as their biolgical mothers were HIV positive.</p></sec><sec id="jve7-sec-0014"><title id="jve7-title-0016">Mean clinical and laboratory parameters in HIV-positive children and controls</title><p id="jve7-para-0030">The HIV-positive children were significantly lighter and shorter compared with the control group, but their BMI did not differ significantly. The control group had a higher mean FBS level compared with the HIV-positive children (<italic>P</italic>=0.009), while the latter had a significantly higher mean serum triglyceride levels (<italic>P</italic><0.001). The mean total cholesterol levels were similar in both groups (<italic>P</italic>=1.0). Although the control group had a higher mean LDL cholesterol and a lower mean HDL cholesterol, the difference was not statistically significant (Table <xref ref-type="table" rid="jve7-tbl-0002">2</xref>).</p><table-wrap id="jve7-tbl-0002" orientation="portrait" position="float"><label>Table 2.</label><caption><p id="jve7-para-0031">Comparison of clinical and laboratory parameters</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col></colgroup><thead><tr><th rowspan="2" colspan="1">Parameters</th><th rowspan="1" colspan="1">All participants</th><th rowspan="1" colspan="1">HIV-positive</th><th rowspan="1" colspan="1">HIV-negative</th><th rowspan="2" colspan="1"><italic>P</italic></th></tr><tr><th rowspan="1" colspan="1">Mean (95%CI)</th><th rowspan="1" colspan="1">Mean (95%CI)</th><th rowspan="1" colspan="1">Mean (95%CI)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Weight (Kg)</td><td rowspan="1" colspan="1">34.6(33.1–6.1)</td><td rowspan="1" colspan="1">31.9(30.1–33.7)</td><td rowspan="1" colspan="1">37.2(34.9–39.5)</td><td rowspan="1" colspan="1"><0.001<xref ref-type="table-fn" rid="jve7-fn-0002">*</xref></td></tr><tr><td rowspan="1" colspan="1">Height(cm)</td><td rowspan="1" colspan="1">137.1(135.2–139.0)</td><td rowspan="1" colspan="1">132.0(129.4–134.6)</td><td rowspan="1" colspan="1">142.1(139.5–144.7)</td><td rowspan="1" colspan="1"><0.001<xref ref-type="table-fn" rid="jve7-fn-0002">*</xref></td></tr><tr><td rowspan="1" colspan="1">BMI(Kg/m<sup>2</sup>)</td><td rowspan="1" colspan="1">17.8(17.5–18.1)</td><td rowspan="1" colspan="1">17.8(17.4–18.2)</td><td rowspan="1" colspan="1">17.8(17.2–18.4)</td><td rowspan="1" colspan="1">0.8</td></tr><tr><td rowspan="1" colspan="1">FBS(mmol/L)</td><td rowspan="1" colspan="1">79.5(78.4–80.6</td><td rowspan="1" colspan="1">78.0(76.4–79.6)</td><td rowspan="1" colspan="1">81.0(79.4–82.6)</td><td rowspan="1" colspan="1">0.009<xref ref-type="table-fn" rid="jve7-fn-0002">*</xref></td></tr><tr><td rowspan="1" colspan="1">Total cholesterol(mg/dL)</td><td rowspan="1" colspan="1">156.6(152.3–160.9)</td><td rowspan="1" colspan="1">156.6(149.4–163.8)</td><td rowspan="1" colspan="1">156.6(151.7–161.5)</td><td rowspan="1" colspan="1">1.0</td></tr><tr><td rowspan="1" colspan="1">HDL-c(mg/dL)</td><td rowspan="1" colspan="1">61.0(58.9–63.1)</td><td rowspan="1" colspan="1">62.9(59.7–66.1)</td><td rowspan="1" colspan="1">59.0(56.3–61.7</td><td rowspan="1" colspan="1">0.07</td></tr><tr><td rowspan="1" colspan="1">LDL-c(mg/dL)</td><td rowspan="1" colspan="1">81.2(77.2–85.1)</td><td rowspan="1" colspan="1">77.4(70.6–84.1)</td><td rowspan="1" colspan="1">85.0(80.9–89.0)</td><td rowspan="1" colspan="1">0.06</td></tr><tr><td rowspan="1" colspan="1">Triglycerides(mg/dL)</td><td rowspan="1" colspan="1">77.7(72.8–82.6)</td><td rowspan="1" colspan="1">87.2(79.4–95.0)</td><td rowspan="1" colspan="1">68.1(62.5–72.7)</td><td rowspan="1" colspan="1"><0.001</td></tr></tbody></table><table-wrap-foot><fn id="jve7-fn-0002"><label>*</label><p id="jve7-para-0032">Statistically significant</p></fn><fn id="jve7-fn-0003"><p id="jve7-para-0033">BMI: body mass index; FBS: fasting blood sugar; HDL-c: high density lipoprotein cholesterol; LDL-c: low density lipoprotein cholesterol</p></fn></table-wrap-foot></table-wrap></sec><sec id="jve7-sec-0015"><title id="jve7-title-0017">Prevalence of dyslipidaemia and hyperglycaemia in HIV-positive children and controls</title><p id="jve7-para-0034">Dyslipidaemia was present in 21.8% and 12.7% of the HIV-positive children and the control group, respectively, with the difference being statistically significant (<italic>P</italic>=0.04). Of the 142 HIV-positive children, 17 (12.0%) had hypercholesterolaemia compared with 7 (4.9%) in the control group (<italic>P</italic>=0.03). There was no difference in the prevalence of hypertriglyceridaemia, decreased HDL-c and increased LDL-c in both groups (Table <xref ref-type="table" rid="jve7-tbl-0003">3</xref>). The two HIV-positive children who were not on ARV drugs had no dyslipidaemia.</p><table-wrap id="jve7-tbl-0003" orientation="portrait" position="float"><label>Table 3.</label><caption><p id="jve7-para-0035">Prevalence of dyslipidaemia and hyperglycaemia in HIV-positive participants age- and sex-matched HIV-negative controls</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col></colgroup><thead><tr><th rowspan="2" colspan="1">Abnormality</th><th rowspan="1" colspan="1">Total participants =284</th><th rowspan="1" colspan="1">HIV-positive participants =142</th><th rowspan="1" colspan="1">HIV-negative participants =142</th><th rowspan="2" colspan="1"><italic>P</italic></th></tr><tr><th rowspan="1" colspan="1"><italic>n</italic> (%)</th><th rowspan="1" colspan="1"><italic>n (%)</italic></th><th rowspan="1" colspan="1"><italic>n</italic> (%)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Dyslipidaemia</td><td rowspan="1" colspan="1">49(17.3)</td><td rowspan="1" colspan="1">31(21.8)</td><td rowspan="1" colspan="1">18(12.7)</td><td rowspan="1" colspan="1">0.04<xref ref-type="table-fn" rid="jve7-fn-0004">*</xref></td></tr><tr><td rowspan="1" colspan="1"> Hypercholesterolaemia</td><td rowspan="1" colspan="1">24(8.5)</td><td rowspan="1" colspan="1">17(12.0)</td><td rowspan="1" colspan="1">7(4.9)</td><td rowspan="1" colspan="1">0.03<xref ref-type="table-fn" rid="jve7-fn-0004">*</xref></td></tr><tr><td rowspan="1" colspan="1"> Low HDL-c</td><td rowspan="1" colspan="1">13(4.6)</td><td rowspan="1" colspan="1">7(4.9)</td><td rowspan="1" colspan="1">6(4.2)</td><td rowspan="1" colspan="1">0.78</td></tr><tr><td rowspan="1" colspan="1"> High LDL-c</td><td rowspan="1" colspan="1">15(5.3)</td><td rowspan="1" colspan="1">9(6.3)</td><td rowspan="1" colspan="1">6(4.2)</td><td rowspan="1" colspan="1">0.43</td></tr><tr><td rowspan="1" colspan="1"> Hypertriglyceridaemia</td><td rowspan="1" colspan="1">18(6.3)</td><td rowspan="1" colspan="1">13(9.2)</td><td rowspan="1" colspan="1">5(3.5)</td><td rowspan="1" colspan="1">0.05</td></tr><tr><td rowspan="1" colspan="1">Hyperglycaemia</td><td rowspan="1" colspan="1">2(0.7)</td><td rowspan="1" colspan="1">1(0.7)</td><td rowspan="1" colspan="1">1(0.7)</td><td rowspan="1" colspan="1">1.00</td></tr></tbody></table><table-wrap-foot><fn id="jve7-fn-0004"><label>*</label><p id="jve7-para-0036">Statistically significant</p></fn><fn id="jve7-fn-0005"><p id="jve7-para-0037">HDL-c: high density lipoprotein cholesterol; LDL-c: low density lipoprotein cholesterol</p></fn></table-wrap-foot></table-wrap></sec><sec id="jve7-sec-0016"><title id="jve7-title-0018">Factors associated with dyslipidaemia in HIV-positive children and controls</title><p id="jve7-para-0038">Among HIV-positive children, those who received an ARV drug combination therapy with LPV/r were significantly more likely to have hypercholesterolaemia, hypertriglyceridaemia and increased LDL-c (Table <xref ref-type="table" rid="jve7-tbl-0004">4</xref>). Furthermore, children with a longer duration on LPV/r were more likely to have hypercholesterolaemia: 221.8 weeks (95% CI 209.8–233.8) <italic>vs</italic> 141.3 weeks (95% CI 123.6–159.0; <italic>P</italic>=0.02). The duration on LPV/r did not, however, affect the prevalence of hypertriglyceridaemia: 190.5 weeks (95% CI 174.2–206.8) <italic>vs</italic> 163.1 weeks (95% CI 145.7–180.5 weeks; <italic>P</italic>=0.66); or high LDL-c: 185.3 weeks (95% CI 169.3–201.3) <italic>vs</italic> 163.7 weeks (95% CI 146.1–181.3; <italic>P</italic>=0.59). Children with no significant and mild disease had a significantly higher prevalence of hypercholesterolaemia (<italic>P</italic>=0.01). When multivariate logistic regression was used, there was still a significant association between the use of LPV/r, immunological staging and the presence of hypercholesterolaemia.</p><table-wrap id="jve7-tbl-0004" orientation="portrait" position="float"><label>Table 4.</label><caption><p id="jve7-para-0039">Factors associated with hypercholesterolaemia and hypertriglyceridaemia in the HIV-positive participants</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col></colgroup><thead><tr><th rowspan="2" colspan="1">Characteristic (<italic>n</italic>)</th><th colspan="2" rowspan="1">Raised cholesterol, total participants=17</th><th rowspan="2" colspan="1"><italic>P</italic></th><th colspan="2" rowspan="1">Raised triglycerides, total participants=13</th><th rowspan="2" colspan="1"><italic>P</italic></th></tr><tr><th rowspan="1" colspan="1"><italic>n</italic> (%)</th><th rowspan="1" colspan="1">OR (95% CI)</th><th rowspan="1" colspan="1"><italic>n</italic> (%)</th><th rowspan="1" colspan="1">OR (95%CI)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Male (69)</td><td rowspan="1" colspan="1">10(14.5)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">7(10.1)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Female(73)</td><td rowspan="1" colspan="1">7(9.6)</td><td rowspan="1" colspan="1">1.6(0.6–4.5)</td><td rowspan="1" colspan="1">0.19</td><td rowspan="1" colspan="1">6(8.2)</td><td rowspan="1" colspan="1">1.3(0.4–4.0)</td><td rowspan="1" colspan="1">0.35</td></tr><tr><td rowspan="1" colspan="1">Socio-economic status</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Upper(24)</td><td rowspan="1" colspan="1">1(4.2)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">2(8.3)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Middle(36)</td><td rowspan="1" colspan="1">8(22.2)</td><td rowspan="1" colspan="1">6.6(0.8–56.5)</td><td rowspan="1" colspan="1">0.09</td><td rowspan="1" colspan="1">3(8.3)</td><td rowspan="1" colspan="1">1.0(0.2–6.5)</td><td rowspan="1" colspan="1">1.0</td></tr><tr><td rowspan="1" colspan="1"> Lower(82)</td><td rowspan="1" colspan="1">8(9.8)</td><td rowspan="1" colspan="1">2.5(0.3–20.9)</td><td rowspan="1" colspan="1">0.40</td><td rowspan="1" colspan="1">8(9.8)</td><td rowspan="1" colspan="1">1.2(0.2–6.0)</td><td rowspan="1" colspan="1">0.8</td></tr><tr><td rowspan="1" colspan="1">Second-hand smoking</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Yes(24)</td><td rowspan="1" colspan="1">1(5.8)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">1(4.2)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> No(118)</td><td rowspan="1" colspan="1">16(94.2)</td><td rowspan="1" colspan="1">0.3(0.01–1.7)</td><td rowspan="1" colspan="1">0.36</td><td rowspan="1" colspan="1">12(10.2)</td><td rowspan="1" colspan="1">0.4(0.01–2.4)</td><td rowspan="1" colspan="1">0.7</td></tr><tr><td rowspan="1" colspan="1">Known family history of heart disease</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Yes(51)</td><td rowspan="1" colspan="1">6(11.8)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">3(5.9)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> No(87)</td><td rowspan="1" colspan="1">10(11.5)</td><td rowspan="1" colspan="1">1.2(0.4–2.5)</td><td rowspan="1" colspan="1">0.98</td><td rowspan="1" colspan="1">10(11.5)</td><td rowspan="1" colspan="1">1.6(0.6–4.4)</td><td rowspan="1" colspan="1">0.92</td></tr><tr><td rowspan="1" colspan="1">BMI</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Normal(125)</td><td rowspan="1" colspan="1">16(12.8)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">12(9.6)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Low(3)</td><td rowspan="1" colspan="1">0(0.0)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">1(7.7)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> High(14)</td><td rowspan="1" colspan="1">1(7.1)</td><td rowspan="1" colspan="1">0.5(0.06–4.3)</td><td rowspan="1" colspan="1">0.5</td><td rowspan="1" colspan="1">0(0.0)</td><td rowspan="1" colspan="1">4.7(0.4–55.8)</td><td rowspan="1" colspan="1">0.2</td></tr><tr><td rowspan="1" colspan="1">WHO clinical staging</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> 1 and 2(90)</td><td rowspan="1" colspan="1">11(12.1)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">8(8.9)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> 3 and 4(52)</td><td rowspan="1" colspan="1">6(11.8)</td><td rowspan="1" colspan="1">1.0(0.3–2.8)</td><td rowspan="1" colspan="1">0.9</td><td rowspan="1" colspan="1">5(9.6)</td><td rowspan="1" colspan="1">1.1(0.3–3.5)</td><td rowspan="1" colspan="1">0.88</td></tr><tr><td rowspan="1" colspan="1">WHO immunological staging</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Not significant and mild(117)</td><td rowspan="1" colspan="1">17(14.5)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">9(7.7)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Advanced and severe(25)</td><td rowspan="1" colspan="1">0(0.0)</td><td rowspan="1" colspan="1"><xref ref-type="table-fn" rid="jve7-fn-0007">**</xref></td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">4(16.0)</td><td rowspan="1" colspan="1">2.3(0.6–8.0)</td><td rowspan="1" colspan="1">0.11</td></tr><tr><td rowspan="1" colspan="1">ARV combinations</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> First-line(104)</td><td rowspan="1" colspan="1">5(4.8)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">6(5.8)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Second-line(36)</td><td rowspan="1" colspan="1">12(33.3)</td><td rowspan="1" colspan="1">9.9(3.2–30.8)</td><td rowspan="1" colspan="1"><0.001</td><td rowspan="1" colspan="1">7(19.4)</td><td rowspan="1" colspan="1">3.9(1.2–12.7)</td><td rowspan="1" colspan="1">0.01</td></tr></tbody></table><table-wrap-foot><fn id="jve7-fn-0007"><label>**</label><p id="jve7-para-0041">Undefined</p></fn><fn id="jve7-fn-0008"><p id="jve7-para-0042">ARV: antiretroviral; BMI: body mass index; WHO: World Health Organization</p></fn></table-wrap-foot></table-wrap><p id="jve7-para-0043">The finding of decreased HDL-c in the HIV-positive children was higher in females (Table <xref ref-type="table" rid="jve7-tbl-0005">5</xref>). There was no association among any of the dyslipidaemias, the age at diagnosis and WHO clinical stage of disease in the children. There was no association among age, socio-economic status, second-hand smoking, known family history of CVD and dyslipidaemia in both HIV-positive children and controls.</p><table-wrap id="jve7-tbl-0005" orientation="portrait" position="float"><label>Table 5.</label><caption><p id="jve7-para-0044">Factors associated with low HDL-c and high LDL-c in the HIV-positive participants</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col></colgroup><thead><tr><th rowspan="2" colspan="1">Characteristic (<italic>n</italic>)</th><th colspan="2" rowspan="1">Lowered HDL-c, total participants=7</th><th rowspan="2" colspan="1"><italic>P</italic></th><th colspan="2" rowspan="1">Raised LDL-c, total participants=9</th><th rowspan="2" colspan="1"><italic>P</italic></th></tr><tr><th rowspan="1" colspan="1"><italic>n</italic> (%)</th><th rowspan="1" colspan="1">OR (95% CI)</th><th rowspan="1" colspan="1"><italic>n</italic> (%)</th><th rowspan="1" colspan="1">OR (95%CI)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Male (69)</td><td rowspan="1" colspan="1">1(1.4)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">7(10.1)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Female(73)</td><td rowspan="1" colspan="1">6(8.2)</td><td rowspan="1" colspan="1">1.6(0.6–4.5)</td><td rowspan="1" colspan="1">0.19</td><td rowspan="1" colspan="1">6(8.2)</td><td rowspan="1" colspan="1">1.3(0.4–4.0)</td><td rowspan="1" colspan="1">0.35</td></tr><tr><td rowspan="1" colspan="1">Socio-economic status</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Upper(24)</td><td rowspan="1" colspan="1">1(4.2)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">1(4.2)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Middle(36)</td><td rowspan="1" colspan="1">3(8.3)</td><td rowspan="1" colspan="1">2.1(0.2–21.4)</td><td rowspan="1" colspan="1">0.54</td><td rowspan="1" colspan="1">4(11.1)</td><td rowspan="1" colspan="1">2.9(0.3–27.4)</td><td rowspan="1" colspan="1">0.36</td></tr><tr><td rowspan="1" colspan="1"> Lower(82)</td><td rowspan="1" colspan="1">3(3.7)</td><td rowspan="1" colspan="1">0.8(0.09–8.8)</td><td rowspan="1" colspan="1">0.91</td><td rowspan="1" colspan="1">4(4.9)</td><td rowspan="1" colspan="1">1.2(0.1–11.1)</td><td rowspan="1" colspan="1">0.89</td></tr><tr><td rowspan="1" colspan="1">Second-hand smoking</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Yes(24)</td><td rowspan="1" colspan="1">3(12.5)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">1(4.2)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> No(118)</td><td rowspan="1" colspan="1">4(3.5)</td><td rowspan="1" colspan="1">4.0(0.7–20.8)</td><td rowspan="1" colspan="1">0.06</td><td rowspan="1" colspan="1">8(6.8)</td><td rowspan="1" colspan="1">0.6(0.03–4.0)</td><td rowspan="1" colspan="1">0.35</td></tr><tr><td rowspan="1" colspan="1">Known family history of heart disease</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Yes(51)</td><td rowspan="1" colspan="1">3(5.9)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">3(5.9)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> No(87)</td><td rowspan="1" colspan="1">4(4.6)</td><td rowspan="1" colspan="1">1.2(0.4–3.7)</td><td rowspan="1" colspan="1">0.77</td><td rowspan="1" colspan="1">6(6.9)</td><td rowspan="1" colspan="1">0.7(0.2–2.2)</td><td rowspan="1" colspan="1">0.51</td></tr><tr><td rowspan="1" colspan="1">BMI</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Normal(125)</td><td rowspan="1" colspan="1">5(4.0)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">12(9.6)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Low(3)</td><td rowspan="1" colspan="1">1(33.3)</td><td rowspan="1" colspan="1">12(0.9–155.5)</td><td rowspan="1" colspan="1">0.06</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> High(14)</td><td rowspan="1" colspan="1">1(7.1)</td><td rowspan="1" colspan="1">1.8(0.2–17.0)</td><td rowspan="1" colspan="1">0.59</td><td rowspan="1" colspan="1">1(7.1)</td><td rowspan="1" colspan="1">1.1(0.1–9.7)</td><td rowspan="1" colspan="1">0.92</td></tr><tr><td rowspan="1" colspan="1">WHO clinical staging</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> 1 and 2(90)</td><td rowspan="1" colspan="1">6(6.7)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">4(3.4)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> 3 and 4(52)</td><td rowspan="1" colspan="1">1(14.3)</td><td rowspan="1" colspan="1">0.3(0.01–1.9)</td><td rowspan="1" colspan="1">0.11</td><td rowspan="1" colspan="1">3(12.0)</td><td rowspan="1" colspan="1">3.8(0.7–9.7)</td><td rowspan="1" colspan="1">0.06</td></tr><tr><td rowspan="1" colspan="1">WHO immunological staging</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Not significant and mild(117)</td><td rowspan="1" colspan="1">4(3.4)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">8(6.8)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Advanced and severe(25)</td><td rowspan="1" colspan="1">3(12.0)</td><td rowspan="1" colspan="1">3.9(0.8–18.4)</td><td rowspan="1" colspan="1">0.06</td><td rowspan="1" colspan="1">1(4.0)</td><td rowspan="1" colspan="1">0.6(0.02–3.8)</td><td rowspan="1" colspan="1">0.34</td></tr><tr><td rowspan="1" colspan="1">ARV combinations</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> First-line(104)</td><td rowspan="1" colspan="1">5(4.7)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">1(0.9)</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"> Second-line(36)</td><td rowspan="1" colspan="1">2(5.9)</td><td rowspan="1" colspan="1">1.3(0.2–6.7)</td><td rowspan="1" colspan="1">0.42</td><td rowspan="1" colspan="1">8(23.5)</td><td rowspan="1" colspan="1">31.3(4.7–728.1)</td><td rowspan="1" colspan="1"><0.001<xref ref-type="table-fn" rid="jve7-fn-0009">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="jve7-fn-0009"><label>*</label><p id="jve7-para-0045">Statistically significant</p></fn><fn id="jve7-fn-0010"><p id="jve7-para-0046">ARV: antiretroviral; BMI: body mass index; HDL-c: high density lipoprotein cholesterol; LDL-c: low density lipoprotein cholesterol; WHO: World Health Organization</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="jve7-sec-0017"><title id="jve7-title-0019">Discussion</title><p id="jve7-para-0047">This descriptive cross-sectional study investigated serum lipid and glucose profiles, which are documented risk factors for later development of CVD, in 142 HIV-positive children and compared them with age- and sex-matched controls. It also identified the relationship of certain parameters such as age, clinical and immunological stage of disease, and the use of various ARV combinations between dyslipidaemia in participants.</p><p id="jve7-para-0048">The prevalence of dyslipidaemia in HIV-positive children in this study was 21.8%, a finding that is similar to that from other studies, ranging between 19.3% and 48% <xref rid="jve7-bib-0017" ref-type="bibr">[17–19]</xref>. In this study, hypercholesterolaemia was the most common type of dyslipidaemia found and was present in 12.2% of the HIV-positive participants. This is similar to the 13% reported in the US and 14.8% in India <xref rid="jve7-bib-0018" ref-type="bibr">[18]</xref>, but lower than the 27.2% detected by a study in Spain <xref rid="jve7-bib-0020" ref-type="bibr">[20]</xref>.</p><p id="jve7-para-0049">In studies where more HIV-positive children have advanced disease, hypertriglyceridaemia is a common finding. Blazquez <italic>et al.</italic> reported a prevalence rate of 39.8% among HIV-positive children in Spain where 67% of the participants had severe disease and a rate of 83% in a study in Uganda where up to 65% of the children had severe HIV infection. In this study, only 10% of participants had severe infection, which could explain the lower prevalence rate of hypertriglyceridaemia (8.6%) obtained <xref rid="jve7-bib-0020" ref-type="bibr">[20,21]</xref>.</p><p id="jve7-para-0050">Protease inhibitors (PIs) have been significantly associated with dyslipidaemia in other studies <xref rid="jve7-bib-0022" ref-type="bibr">[22]</xref>, a finding also in this study where the use of second-line ARV combinations that contained the protease inhibitor LPV/r was significantly associated with hypercholesterolaemia, hypertriglyceridaemia and increased LDL-c when compared with participants on first-line drugs. In a study by Aldrovandi <italic>et al.</italic><xref rid="jve7-bib-0023" ref-type="bibr">[23]</xref>, PI use was associated with elevated triglycerides among 52% of HIV-positive children while Carter <italic>et al.</italic> found a significant association between the use of multiple PIs and hypercholesterolaemia <xref rid="jve7-bib-0024" ref-type="bibr">[24]</xref>. Kamara <italic>et al</italic>. found that individuals on LPV/r had the worst triglyceride profile compared with those on other PIs <xref rid="jve7-bib-0025" ref-type="bibr">[25]</xref>.</p><p id="jve7-para-0051">In Aldrovandi <italic>et al</italic>. <xref rid="jve7-bib-0023" ref-type="bibr">[23]</xref> the use of the NNRTIs nevirapine (NVP) and efavirenz (EFV) was linked to a high HDL-c value, also known as ‘good’ cholesterol. Therefore, it is not surprising that 95.1% of the HIV-positive children in this study had high HDL-c levels because 72% of them were on ARV combinations that contained either NVP or EFV. A study in Zimbabwe found that children on (zidovudine) ZDV had lower total cholesterol, HDL-c and TG than those on NVP or EFV <xref rid="jve7-bib-0026" ref-type="bibr">[26]</xref>. Also, decreased serum concentrations of HDL-c in individuals who are ARV naive has been shown to point to chronic inflammation <xref rid="jve7-bib-0027" ref-type="bibr">[27]</xref>. Participants in this study had a significantly higher mean serum HDL-c compared with the control group, which could imply good control of chronic inflammation. Decreased HDL-c was the least common of the dyslipidaemias and this has also been shown in several other studies <xref rid="jve7-bib-0028" ref-type="bibr">[28–30]</xref>.</p><p id="jve7-para-0052">Only one study participant and one control group member had an FBS level of greater than 100mg/dL, a finding that is in keeping with studies from Brazil and Thailand where no children had elevated FBS levels <xref rid="jve7-bib-0031" ref-type="bibr">[31,32]</xref>. The latter study showed that the prevalence of increased FBS was low in patients on NNRTIs (NVP or EFV), a finding also present in this study. The child who had elevated FBS was, however, on an ARV combination that had two NRTIs (lamivudine and abacavir) and efavirenz, a combination that has been shown to be associated with insulin resistance <xref rid="jve7-bib-0033" ref-type="bibr">[33]</xref>. There were only three children on this ARV combination and this number is too small to draw up any statistically meaningful conclusions.</p><p id="jve7-para-0053">The virus itself could initiate a systemic inflammatory response in an individual as a result of persistent infection leading to hypertriglyceridaemia <xref rid="jve7-bib-0034" ref-type="bibr">[34]</xref>. In this study, only two children who were newly diagnosed with HIV, were not yet on ARV drugs and had no lipid abnormalities. However, this number is too small to make any statistical conclusion.</p><p id="jve7-para-0054">The present study shows that the mean weight and height were significantly lower in the HIV-positive participants when compared with the control group, a finding that has been found in several studies. It has been attributed to the chronic nature of the disease with its related increase in metabolism and caloric demands, comorbidities, medications and food insecurity <xref rid="jve7-bib-0035" ref-type="bibr">[35]</xref>. In the study population, a higher proportion had a lower socio-economic background, which raises the question of the availability of adequate nutrition <xref rid="jve7-bib-0036" ref-type="bibr">[36]</xref>.</p><p id="jve7-para-0055">An inverse relationship has been found between socio-economic status and smoking, a finding also observed in this study where second-hand smoking was more commonly found in the participants from a lower socio-economic background <xref rid="jve7-bib-0037" ref-type="bibr">[37,38]</xref>.</p><sec id="jve7-sec-0018"><title id="jve7-title-0020">Limitations</title><p id="jve7-para-0056">Due to cost implications, we were not able to assess the presence and prevalence of insulin resistance. There were also very few HIV-positive children attending the PIDC who were not on ARVs making it difficult to compare the effects of ARVs as a whole on lipid profile in HIV-positive children.</p></sec></sec><sec id="jve7-sec-0019"><title id="jve7-title-0021">Conclusion</title><p id="jve7-para-0057">Regular monitoring of the lipid profile of HIV-positive children, especially those on LPV/r, will be clinically useful in determining those who may have a higher CVD risk. Longitudinal and larger multicentre studies will be useful in determining the progression of dyslipidaemias in HIV-positive children over time. Because the safety of only a few ARV drugs has been well established in children, more research is needed to broaden the choice of drugs available for treating HIV infection in these individuals where it may be necessary to switch to other types of PI-based therapy or a different class of ARV <xref rid="jve7-bib-0039" ref-type="bibr">[39,40]</xref>.</p></sec></body><back><ack id="jve7-ack-0001"><title id="jve7-title-0022">Acknowledgements</title></ack><sec id="jve7-sec-0020"><title id="jve7-title-0023"></title><sec id="jve7-sec-0021"><title id="jve7-title-0024">Declaration of interests</title><p id="jve7-para-0058">The authors report no financial or personal interests.</p></sec></sec><sec id="jve7-sec-0022"><title id="jve7-title-0025"></title><sec id="jve7-sec-0023"><title id="jve7-title-0026">Funding</title><p id="jve7-para-0059">The study was funded by the Medical Education Partnership in Nigeria (MEPIN), Jos, Plateau State, Nigeria.</p></sec></sec><ref-list id="jve7-ref-0001"><title>References</title><ref id="jve7-bib-0001"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>AR</given-names></name>,
<name name-style="western"><surname>Siliciano</surname><given-names>RF.</given-names></name></person-group><article-title>Progress toward HIV Eradication: case reports, current efforts, and the challenges associated with cure</article-title>.
<source>Annu Rev Med</source><year>2016</year>;
<volume>67</volume>:
<fpage>215</fpage>–
<lpage>228</lpage>.<pub-id pub-id-type="pmid">26526767</pub-id></mixed-citation></ref><ref id="jve7-bib-0002"><label>2.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>UNAIDS</collab></person-group><source>The Gap Report</source>.
<year>2014</year><comment>Available at:</comment><comment><uri xlink:href="http://www.unaids.org/en/resources/campaigns/2014/2014gapreport/gapreport/">www.unaids.org/en/resources/campaigns/2014/2014gapreport/gapreport/</uri></comment> (
<comment>accessed May 2017</comment>).</mixed-citation></ref><ref id="jve7-bib-0003"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grinspoon</surname><given-names>S</given-names></name>,
<name name-style="western"><surname>Carr</surname><given-names>A.</given-names></name></person-group><article-title>Cardiovascular risk and body-fat abnormalities in HIV-infected adults</article-title>.
<source>N Engl J Med</source><year>2005</year>;
<volume>352</volume>:
<fpage>48</fpage>–
<lpage>62</lpage>.<pub-id pub-id-type="pmid">15635112</pub-id></mixed-citation></ref><ref id="jve7-bib-0004"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>May</surname><given-names>MT</given-names></name>,
<name name-style="western"><surname>Gompels</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Delpech</surname><given-names>V</given-names></name><etal>et al.</etal></person-group><article-title>Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy</article-title>.
<source>AIDS</source><year>2014</year>;
<volume>28</volume>:
<fpage>1193</fpage>–
<lpage>1202</lpage>.<pub-id pub-id-type="pmid">24556869</pub-id></mixed-citation></ref><ref id="jve7-bib-0005"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Francisci</surname><given-names>D</given-names></name>,
<name name-style="western"><surname>Giannini</surname><given-names>S</given-names></name>,
<name name-style="western"><surname>Baldelli</surname><given-names>F</given-names></name><etal>et al.</etal></person-group><article-title>HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction</article-title>.
<source>AIDS</source><year>2009</year>;
<volume>23</volume>:
<fpage>589</fpage>–
<lpage>596</lpage>.<pub-id pub-id-type="pmid">19177019</pub-id></mixed-citation></ref><ref id="jve7-bib-0006"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Husain</surname><given-names>NE</given-names></name>,
<name name-style="western"><surname>Ahmed</surname><given-names>MH.</given-names></name></person-group><article-title>Managing dyslipidemia in HIV/AIDS patients: challenges and solutions</article-title>.
<source>HIV AIDS (Auckl)</source><year>2015</year>;
<volume>7</volume>:
<fpage>1</fpage>–
<lpage>10</lpage>.<pub-id pub-id-type="pmid">25565897</pub-id></mixed-citation></ref><ref id="jve7-bib-0007"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernstein</surname><given-names>L</given-names></name>,
<name name-style="western"><surname>Brook</surname><given-names>K</given-names></name>,
<name name-style="western"><surname>Collado</surname></name></person-group><article-title>Guidelines for the use of antiretroviral agents in pediatric HIV infection</article-title>.
<source>MMWR</source><year>1998</year>;
<volume>47</volume>:
<fpage>1</fpage>–
<lpage>31</lpage>.</mixed-citation></ref><ref id="jve7-bib-0008"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cunha</surname><given-names>J</given-names><prefix>da</prefix></name>,
<name name-style="western"><surname>Maselli</surname><given-names>LM</given-names></name>,
<name name-style="western"><surname>Stern</surname><given-names>AC</given-names></name><etal>et al.</etal></person-group><article-title>Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: old and new drugs</article-title>.
<source>World J Virol</source><year>2015</year>;
<volume>4</volume>:
<fpage>56</fpage>–
<lpage>77</lpage>.<pub-id pub-id-type="pmid">25964872</pub-id></mixed-citation></ref><ref id="jve7-bib-0009"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alomar</surname><given-names>MJ.</given-names></name></person-group><article-title>Factors affecting the development of adverse drug reactions (Review article)</article-title>.
<source>Saudi Pharm J</source><year>2014</year>;
<volume>22</volume>:
<fpage>83</fpage>–
<lpage>94</lpage>.<pub-id pub-id-type="pmid">24648818</pub-id></mixed-citation></ref><ref id="jve7-bib-0010"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nery</surname><given-names>MW</given-names></name>,
<name name-style="western"><surname>Martelli</surname><given-names>CM</given-names></name>,
<name name-style="western"><surname>Silveira</surname><given-names>EA</given-names></name><etal>et al.</etal></person-group><article-title>Cardiovascular risk assessment: a comparison of the Framingham, PROCAM, and DAD equations in HIV-infected persons</article-title>.
<source>Sci World J</source><year>2013</year>;
<volume>2013</volume>:
<fpage>969281</fpage>.</mixed-citation></ref><ref id="jve7-bib-0011"><label>11.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>US Department of Health and Human Services</collab></person-group><source>The health consequences of smoking–50 years of progress: A report of the surgeon general</source>,
<year>2014</year><comment>Atlanta: Services UDoHaH</comment>;
<comment>Available at:</comment><comment><uri xlink:href="http://www.surgeongeneral.gov/library/reports/50-years-of-progress/">www.surgeongeneral.gov/library/reports/50-years-of-progress/</uri></comment> (
<comment>accessed June 2017</comment>).</mixed-citation></ref><ref id="jve7-bib-0012"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shea</surname><given-names>S</given-names></name>,
<name name-style="western"><surname>Ottman</surname><given-names>R</given-names></name>,
<name name-style="western"><surname>Gabrieli</surname><given-names>C</given-names></name><etal>et al.</etal></person-group><article-title>Family history as an independent risk factor for coronary artery disease</article-title>.
<source>J Am Coll Cardiol</source><year>1984</year>;
<volume>4</volume>:
<fpage>793</fpage>–
<lpage>801</lpage>.<pub-id pub-id-type="pmid">6481018</pub-id></mixed-citation></ref><ref id="jve7-bib-0013"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olusanya</surname><given-names>O</given-names></name>,
<name name-style="western"><surname>Okpere</surname><given-names>E</given-names></name></person-group>,
<article-title>M E. The importance of social class in voluntary fertility control in a developing country</article-title>.
<source>West Afr J Med</source><year>1985</year>;
<volume>4</volume>:
<fpage>205</fpage>–
<lpage>212</lpage>.</mixed-citation></ref><ref id="jve7-bib-0014"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eknoyan</surname><given-names>G.</given-names></name></person-group><article-title>Adolphe Quetelet (1796–1874)–the average man and indices of obesity</article-title>.
<source>Nephrol Dial Transplant</source><year>2008</year>;
<volume>23</volume>:
<fpage>47</fpage>–
<lpage>51</lpage>.<pub-id pub-id-type="pmid">17890752</pub-id></mixed-citation></ref><ref id="jve7-bib-0015"><label>15.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>WHO</collab></person-group><source>WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children</source>.
<year>2007</year><comment>Available at:</comment><comment><uri xlink:href="http://www.who.int/hiv/pub/guidelines/hivstaging/en/">www.who.int/hiv/pub/guidelines/hivstaging/en/</uri></comment> (
<comment>accessed May 2017</comment>).</mixed-citation></ref><ref id="jve7-bib-0016"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Expert Panel on Integrated Guidelines for Cardiovascular H, Risk Reduction in C, Adolescents</collab><etal>et al.</etal></person-group><article-title>Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report</article-title>.
<source>Pediatrics</source><year>2011</year>;
<volume>128</volume><issue>Suppl 5</issue>:
<fpage>S213</fpage>–
<lpage>256</lpage>.<pub-id pub-id-type="pmid">22084329</pub-id></mixed-citation></ref><ref id="jve7-bib-0017"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>C</given-names></name>,
<name name-style="western"><surname>Umanski</surname><given-names>G</given-names></name>,
<name name-style="western"><surname>Blank</surname><given-names>A</given-names></name><etal>et al.</etal></person-group><article-title>Comorbidity-related treatment outcomes among HIV-infected adults in the Bronx, NY</article-title>.
<source>J Urban Health</source><year>2011</year>;
<volume>88</volume>:
<fpage>507</fpage>–
<lpage>516</lpage>.<pub-id pub-id-type="pmid">21302140</pub-id></mixed-citation></ref><ref id="jve7-bib-0018"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mandal</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Mukherjee</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Lakshmy</surname><given-names>R</given-names></name><etal>et al.</etal></person-group><article-title>Dyslipidemia in HIV infected children receiving highly active antiretroviral therapy</article-title>.
<source>Indian J Pediatr</source><year>2016</year>;
<volume>83</volume>:
<fpage>226</fpage>–
<lpage>231</lpage>.<pub-id pub-id-type="pmid">26334860</pub-id></mixed-citation></ref><ref id="jve7-bib-0019"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menezes de Padua</surname><given-names>CA</given-names></name>,
<name name-style="western"><surname>Moura</surname><given-names>CS.</given-names></name></person-group><article-title>Availability of data on adverse reactions to antiretroviral drugs in medical charts according to the Naranjo algorithm: an example of a Brazilian historical cohort</article-title>.
<source>Clin Drug Investig</source><year>2014</year>;
<volume>34</volume>:
<fpage>395</fpage>–
<lpage>402</lpage>.</mixed-citation></ref><ref id="jve7-bib-0020"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blazquez</surname><given-names>D</given-names></name>,
<name name-style="western"><surname>Ramos-Amador</surname><given-names>JT</given-names></name>,
<name name-style="western"><surname>Sainz</surname><given-names>T</given-names></name><etal>et al.</etal></person-group><article-title>Lipid and glucose alterations in perinatally-acquired HIV-infected adolescents and young adults</article-title>.
<source>BMC Infect Dis</source><year>2015</year>;
<volume>15</volume>:
<fpage>119</fpage>.<pub-id pub-id-type="pmid">25880777</pub-id></mixed-citation></ref><ref id="jve7-bib-0021"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piloya</surname><given-names>T</given-names></name>,
<name name-style="western"><surname>Bakeera-Kitaka</surname><given-names>S</given-names></name>,
<name name-style="western"><surname>Kekitiinwa</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Kamya</surname><given-names>MR.</given-names></name></person-group><article-title>Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study</article-title>.
<source>J Int AIDS Soc</source><year>2012</year>;
<volume>15</volume>:
<fpage>17427</fpage>.<pub-id pub-id-type="pmid">22814353</pub-id></mixed-citation></ref><ref id="jve7-bib-0022"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tremeschin</surname><given-names>MH</given-names></name>,
<name name-style="western"><surname>Sartorelli</surname><given-names>DS</given-names></name>,
<name name-style="western"><surname>Cervi</surname><given-names>MC</given-names></name><etal>et al.</etal></person-group><article-title>Nutritional assessment and lipid profile in HIV-infected children and adolescents treated with highly active antiretroviral therapy</article-title>.
<source>Rev Soc Bras Med Trop</source><year>2011</year>;
<volume>44</volume>:
<fpage>274</fpage>–
<lpage>281</lpage>.<pub-id pub-id-type="pmid">21739071</pub-id></mixed-citation></ref><ref id="jve7-bib-0023"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aldrovandi</surname><given-names>GM</given-names></name>,
<name name-style="western"><surname>Lindsey</surname><given-names>JC</given-names></name>,
<name name-style="western"><surname>Jacobson</surname><given-names>DL</given-names></name><etal>et al.</etal></person-group><article-title>Morphologic and metabolic abnormalities in vertically HIV-infected children and youth</article-title>.
<source>AIDS</source><year>2009</year>;
<volume>23</volume>:
<fpage>661</fpage>–
<lpage>672</lpage>.<pub-id pub-id-type="pmid">19279441</pub-id></mixed-citation></ref><ref id="jve7-bib-0024"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carter</surname><given-names>RJ</given-names></name>,
<name name-style="western"><surname>Wiener</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Abrams</surname><given-names>EJ</given-names></name><etal>et al.</etal></person-group><article-title>Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999–2004: a longitudinal analysis</article-title>.
<source>J Acquir Immune Defic Syndr</source><year>2006</year>;
<volume>41</volume>:
<fpage>453</fpage>–
<lpage>460</lpage>.<pub-id pub-id-type="pmid">16652053</pub-id></mixed-citation></ref><ref id="jve7-bib-0025"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamara</surname><given-names>DA</given-names></name>,
<name name-style="western"><surname>Smith</surname><given-names>C</given-names></name>,
<name name-style="western"><surname>Ryom</surname><given-names>L</given-names></name><etal>et al.</etal></person-group><article-title>Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study</article-title>.
<source>Antivir Ther</source><year>2016</year>;
<volume>21</volume>:
<fpage>495</fpage>–
<lpage>506</lpage>.<pub-id pub-id-type="pmid">27114439</pub-id></mixed-citation></ref><ref id="jve7-bib-0026"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bwakura-Dangarembizi</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Musiime</surname><given-names>V</given-names></name>,
<name name-style="western"><surname>Szubert</surname><given-names>AJ</given-names></name><etal>et al.</etal></person-group><article-title>Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy</article-title>.
<source>Pediatr Infect Dis J</source><year>2015</year>;
<volume>34</volume>:
<fpage>e23</fpage>–
<lpage>31</lpage>.<pub-id pub-id-type="pmid">25068287</pub-id></mixed-citation></ref><ref id="jve7-bib-0027"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rose</surname><given-names>H</given-names></name>,
<name name-style="western"><surname>Woolley</surname><given-names>I</given-names></name>,
<name name-style="western"><surname>Hoy</surname><given-names>J</given-names></name><etal>et al.</etal></person-group><article-title>HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment</article-title>.
<source>Metabolism</source><year>2006</year>;
<volume>55</volume>:
<fpage>90</fpage>–
<lpage>95</lpage>.<pub-id pub-id-type="pmid">16324925</pub-id></mixed-citation></ref><ref id="jve7-bib-0028"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brewinski</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Megazzini</surname><given-names>K</given-names></name>,
<name name-style="western"><surname>Hance</surname><given-names>LF</given-names></name><etal>et al.</etal></person-group><article-title>Dyslipidemia in a cohort of HIV-infected Latin American children receiving highly active antiretroviral therapy</article-title>.
<source>J Trop Pediatr</source><year>2011</year>;
<volume>57</volume>:
<fpage>324</fpage>–
<lpage>332</lpage>.<pub-id pub-id-type="pmid">20889625</pub-id></mixed-citation></ref><ref id="jve7-bib-0029"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hazra</surname><given-names>R</given-names></name>,
<name name-style="western"><surname>Cohen</surname><given-names>RA</given-names></name>,
<name name-style="western"><surname>Gonin</surname><given-names>R</given-names></name><etal>et al.</etal></person-group><article-title>Lipid levels in the second year of life among HIV-infected and HIV-exposed uninfected Latin American children</article-title>.
<source>AIDS</source><year>2012</year>;
<volume>26</volume>:
<fpage>235</fpage>–
<lpage>240</lpage>.<pub-id pub-id-type="pmid">22008654</pub-id></mixed-citation></ref><ref id="jve7-bib-0030"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Viganoa</surname><given-names>TC</given-names></name>,
<name name-style="western"><surname>Brambilla</surname><given-names>P</given-names></name>,
<name name-style="western"><surname>Newell</surname><given-names>ML.</given-names></name></person-group><article-title>Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe</article-title>.
<source>AIDS</source><year>2004</year>;
<volume>18</volume>:
<fpage>1443</fpage>–
<lpage>1451</lpage>.<pub-id pub-id-type="pmid">15199321</pub-id></mixed-citation></ref><ref id="jve7-bib-0031"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>B</given-names></name>,
<name name-style="western"><surname>Aurpibul</surname><given-names>L</given-names></name>,
<name name-style="western"><surname>Sirisanthana</surname><given-names>V</given-names></name><etal>et al.</etal></person-group><article-title>Low prevalence of insulin resistance among HIV-infected children receiving nonnucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thailand</article-title>.
<source>HIV Med</source><year>2009</year>;
<volume>10</volume>:
<fpage>72</fpage>–
<lpage>78</lpage>.<pub-id pub-id-type="pmid">19018877</pub-id></mixed-citation></ref><ref id="jve7-bib-0032"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papi</surname><given-names>L</given-names></name>,
<name name-style="western"><surname>Menezes</surname><given-names>AC</given-names></name>,
<name name-style="western"><surname>Rocha</surname><given-names>H</given-names></name><etal>et al.</etal></person-group><article-title>Prevalence of lipodystrophy and risk factors for dyslipidemia in HIV-infected children in Brazil</article-title>.
<source>Braz J Infect Dis</source><year>2014</year>;
<volume>18</volume>:
<fpage>394</fpage>–
<lpage>399</lpage>.<pub-id pub-id-type="pmid">24794884</pub-id></mixed-citation></ref><ref id="jve7-bib-0033"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galindo</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Amariles</surname><given-names>P</given-names></name>,
<name name-style="western"><surname>Mueses-Marin</surname><given-names>HF</given-names></name><etal>et al.</etal></person-group><article-title>Effectiveness and safety of generic version of abacavir/lamivudine and efavirenz in treatment naive HIV-infected patients: a nonrandomized, open-label, phase IV study in Cali-Colombia, 2011–2012</article-title>.
<source>BMC Infect Dis</source><year>2016</year>;
<volume>16</volume>:
<fpage>532</fpage>.<pub-id pub-id-type="pmid">27716093</pub-id></mixed-citation></ref><ref id="jve7-bib-0034"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grunfeld</surname><given-names>C</given-names></name>,
<name name-style="western"><surname>Pang</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Doerrler</surname><given-names>W</given-names></name><etal>et al.</etal></person-group><article-title>Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome</article-title>.
<source>J Clin Endocrinol Metab</source><year>1992</year>;
<volume>74</volume>:
<fpage>1045</fpage>–
<lpage>1052</lpage>.<pub-id pub-id-type="pmid">1373735</pub-id></mixed-citation></ref><ref id="jve7-bib-0035"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kimani-Murage</surname><given-names>EW</given-names></name>,
<name name-style="western"><surname>Norris</surname><given-names>SA</given-names></name>,
<name name-style="western"><surname>Pettifor</surname><given-names>JM</given-names></name><etal>et al.</etal></person-group><article-title>Nutritional status and HIV in rural South African children</article-title>.
<source>BMC Pediatr</source><year>2011</year>;
<volume>11</volume>:
<fpage>23</fpage>.<pub-id pub-id-type="pmid">21439041</pub-id></mixed-citation></ref><ref id="jve7-bib-0036"><label>36.</label><mixed-citation publication-type="report"><person-group person-group-type="author"><name name-style="western"><surname>Legg</surname><given-names>C</given-names></name>,
<name name-style="western"><surname>Kormawa</surname><given-names>P</given-names></name>,
<name name-style="western"><surname>Maziya-Dixon</surname><given-names>B</given-names></name><etal>et al.</etal></person-group><article-title>Report on mapping livelihoods and nutrition in Nigeria using data from the national rural livelihoods survey and the national food consumption and nutrition survey</article-title>.
<source>International Institute of Tropical Agriculture</source><year>2005</year>.</mixed-citation></ref><ref id="jve7-bib-0037"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feinstein</surname><given-names>JS.</given-names></name></person-group><article-title>The relationship between socioeconomic status and health: a review of the literature</article-title>.
<source>Milbank Q</source><year>1993</year>;
<volume>71</volume>:
<fpage>279</fpage>–
<lpage>322</lpage>.<pub-id pub-id-type="pmid">8510603</pub-id></mixed-citation></ref><ref id="jve7-bib-0038"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitter</surname><given-names>SS</given-names></name>,
<name name-style="western"><surname>Vedanthan</surname><given-names>R</given-names></name>,
<name name-style="western"><surname>Islami</surname><given-names>F</given-names></name><etal>et al.</etal></person-group><article-title>Household fuel use and cardiovascular disease mortality: Golestan cohort study</article-title>.
<source>Circulation</source><year>2016</year>;
<volume>133</volume>:
<fpage>2360</fpage>–
<lpage>2369</lpage>.<pub-id pub-id-type="pmid">27297340</pub-id></mixed-citation></ref><ref id="jve7-bib-0039"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinez</surname><given-names>E</given-names></name>,
<name name-style="western"><surname>Garcia-Viejo</surname><given-names>MA</given-names></name>,
<name name-style="western"><surname>Blanco</surname><given-names>JL</given-names></name><etal>et al.</etal></person-group><article-title>Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy</article-title>.
<source>Clin Infect Dis</source><year>2000</year>;
<volume>31</volume>:
<fpage>1266</fpage>–
<lpage>1273</lpage>.<pub-id pub-id-type="pmid">11073762</pub-id></mixed-citation></ref><ref id="jve7-bib-0040"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiang</surname><given-names>N</given-names></name>,
<name name-style="western"><surname>James</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Walters</surname><given-names>S</given-names></name><etal>et al.</etal></person-group><article-title>Improved serum cholesterol in paediatric patients switched from suppressive lopinavir-based therapy to boosted darunavir or atazanavir: an 18-month retrospective study</article-title>.
<source>HIV Med</source><year>2014</year>;
<volume>15</volume>:
<fpage>635</fpage>–
<lpage>636</lpage>.<pub-id pub-id-type="pmid">25334035</pub-id></mixed-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E51 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000E51 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:5518245
|texte= Serum lipid and glucose profiles in HIV-positive Nigerian children
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:28758024" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |